why choose us

Clinical Trials Search

Showing 19,670 of 132,963 result(s)
Immuno-nutrition Supplementation in Haemodialysis

Status: Completed

Condition: Chronic Kidney Disease Requiring Chronic Dialysis

Interventions: Interventional

Date: 2022-09-05

Anterior Cruciate Ligament (ACL) Reconstruction With Bone Tendon Bone Autograft With Versus Without Internal Bracing

Status: NOT_YET_RECRUITING

Condition: ACL Tear

Interventions: The ACL will be reconstructed using a participant's own patella tendon (BTB autograft), and the graft will be fortified by suture tape during the

Date: 2022-09-04

Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children

Status: Completed

Condition: Vaccine Reaction

Interventions: SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT.
Bio Farma

Date: 2022-09-04

Conservative Versus Operative - First Time Patella Dislocations

Status: NOT_YET_RECRUITING

Condition: Patella Dislocation

Interventions: Surgery to correct dislocated (knocked out of place) knee cap.
This surgery anchors the kneecap back into the correct position and supports the k

Date: 2022-09-04

Conservative Versus Operative - Frist Time Shoulder Dislocations

Status: NOT_YET_RECRUITING

Condition: Shoulder Dislocation

Interventions: Participants in this group will undergo minimally invasive surgery to repair their shoulder with a technique called a Bankart repair.

Date: 2022-09-04

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Status: Completed

Condition: Advanced Solid Tumors

Interventions:

Tablets

Route of Administration: Oral

Date: 2022-09-04

HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC

Status: COMPLETED

Condition: Liver Cancer

Interventions: Patients with unresectable hepatocellular carcinoma will receive hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization c

Date: 2022-09-04

Biomarkers Predicting Acute Myocardial Infraction in Patients Without Standard Modifiable Risk Factors

Status: COMPLETED

Condition: Cardiovascular Diseases

Interventions: Complete and comprehensive medical interview will be conducted in each eligible patient after revascularization.
In addition, patient's labo

Date: 2022-09-03

Phase I;II Study of Pacritinib, A JAK2;IRAK1;CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Status: Completed

Condition: Graft vs Host Disease

Interventions: Pacritinib will be given as 100 mg or 200 mg tablets to be taken orally twice daily (12 hours apart) on days 1-28 of a 28 day cycle.
Morning and

Date: 2022-09-03

BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Status: Completed

Condition: Metastatic Pancreatic Ductal Adenocarcinoma

Interventions: BXCL701 0.3 mg, orally, twice a day on days 1-14 every 21 days

Date: 2022-09-02